ES2134459T3 - Indeno(1,2-e)pirazina-4-onas, su preparacion y los medicamentos que les contienen. - Google Patents

Indeno(1,2-e)pirazina-4-onas, su preparacion y los medicamentos que les contienen.

Info

Publication number
ES2134459T3
ES2134459T3 ES95914403T ES95914403T ES2134459T3 ES 2134459 T3 ES2134459 T3 ES 2134459T3 ES 95914403 T ES95914403 T ES 95914403T ES 95914403 T ES95914403 T ES 95914403T ES 2134459 T3 ES2134459 T3 ES 2134459T3
Authority
ES
Spain
Prior art keywords
pct
receptor
pirazina
onas
indeno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95914403T
Other languages
English (en)
Inventor
Jean-Claude Aloup
Francois Audiau
Michel Barreau
Dominique Damour
Arielle Genevois-Borella
Patrick Jimonet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Application granted granted Critical
Publication of ES2134459T3 publication Critical patent/ES2134459T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPUESTOS DE LA FORMULA (I) CONDE R ES UN ATOMO DE NITROGENO, OXIGENO O AZUFRE SUSTITUIDO O UN RADICAL C=R{SUB,3}, C(R{SUB,4}R{SUB,5} O CH-R{SUB,6}; R{SUB,1} ES UN RADICAL HIDROXI, POLIFLUOROALCOXI, CARBOXI, ALCOXICARBONIL, -NH-CHO O -NH-CON(ALQ)AR DONDE AR ES OPCIONALMENTE SUSTITUIDO, -N(ALQ)-CONR{SUB,8}R{SUB,9}, -N(ALQ-AR)-CO-NR{SUB,8}R{SUB,9}, -NH-CONR{SUB,9}R{SUB,12}, -NH-CS-NR{SUB,8}R{SUB,9}, N-(ALQ)-CSNR{SUB,8}R{SUB,9}, -NH-CO-R{SUB,10}, -NH-CS-R{SUB,20}, -NHC(=NR{SUB,21}-NR{SUB,7}R{SUB,9}, SO{SUB,2}-NR{SUB,7}R{SUB,9}, OPCIONALMENTE 3-SUSTITUIDO 2-OXO-1-IMIDAZOLIDINIL U OPCIONALMENTE 3-SUSTITUIDO 2-OXO-1 PERHIDROPIRIMIDINIL; R{SUB,2} ES UN ATOMO DE HIDROGENO O HALOGENO O UN RADICAL ALQUILO, ALCOXI, AMINO, NHCO-NH-AR, N=CH.N(ALQ)ALQ'', NITRO, CIANO, FENIL, IMIDAZOLIL, ACILAMINO, SO{SUB,3}H, HIDROXI, POLIFLUOROALCOXI, CARBOXI, ALCOXICARBONIL, -NH-CHO, -NH-CO-N(ALQ)AR EN DONDE AR ES OPCIONALMENTE SUSTITUIDO, -N(ALQ)-CO-NR{SUB,8}R{SUB,9}, -NHSO{SUB,2}-NR{SUB,7}R{SUB,9}, -N(ALQ-AR)-CO-NR{SUB,8}R{SUB,9}, NH-CO-NR{SUB,9}R{SUB,12}, -NH-CS-NR{SUB,8}R{SUB,9}, -N(ALQ)-CSNR{SUB,8}R{SUB,9}, -NH-CO-R{SUB,10}, -NH-CS-R{SUB,20}, -NHC(NR{SUB,21})NR{SUB,7}R{SUB,9}, -NH-SO{SUB,2}-NR{SUB,7}R{SUB,9}, N-(ALQ)-SO{SUB,2}-NR{SUB,7}R{SUB,9}, -CO-NR{SUB,7}R{SUB,9}, -NHSO{SUB,2}ALQ, -NR{SUB,9}R{SUB,11}, -S(O){SUB,M}-ALQ-AR, SO{SUB,2}-NR{SUB,7}R{SUB,9}, OPCIONALMENTE 3-SUSTITUIDO 2-OXO-1IMIDAZOLIDINIL U OPCIONALMENTE 3-SUSTITUIDO 2-OXO-1PERHIDROPIRIMIDINIL; R{SUB,3} ES UN ATOMO DE OXIGENO O UN RADICAL NOH, NO-ALQ-COOX O CH-R{SUB,13}, R{SUB,4} ES UN RADICAL ALQUIL, -ALQ-HET O ALQ-AR; R{SUB,5} ES UN RADICAL ALQUILO C{SUB,1-11} RECTO O RAMIFICADO, ALQ-HET O ALQ-AR, O R{SUB,4} Y R{SUB,5} TOMADOS JUNTO CON EL ATOMO DE CARBONO AL QUE ESTAN UNIDOS FORMAN UN RADICAL CICLOALQUILO; R{SUB,6} ES UN RADICAL DE UN ATOMO DE HIDROGENO O UN RADICAL HIDROXI, O ALQUIL RECTO O RAMIFICADO C{SUB,1}-{SUB,11}, -NR{SUB,14}R{SUB,15}, -ALQ-HO, ALQNR{SUB,14}R{SUB,15}, ALQ-AR O -ALQ-HET; O SALES DE LOS MISMOS. LOS COMPUESTOS DE LA FORMULA (I) SON ANTAGONISTAS DEL RECEPTOR N-METIL-ASPARTATO- (NMDA) NO COMPETITIVOS, EN CONCRETO LIGANDOS DEL LUGAR DE MODULACION DE LA GLICINA RECEPTORA NMDA, Y SON ANTAGONISTAS DEL RECEPTOR DEL ACIDO ALFA-AMINO-3-HIDROXI-5-METIL4-ISOXAZOLAPROPIONICO, SIENDO TAMBIEN CONOCIDO DICHO RECEPTOR COMO RECEPTOR QUISCUALATO.
ES95914403T 1994-03-28 1995-03-23 Indeno(1,2-e)pirazina-4-onas, su preparacion y los medicamentos que les contienen. Expired - Lifetime ES2134459T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9403581A FR2717812B1 (fr) 1994-03-28 1994-03-28 Indeno[1,2-e]pyrazine-4-ones, leur préparation et les médicaments les contenant.

Publications (1)

Publication Number Publication Date
ES2134459T3 true ES2134459T3 (es) 1999-10-01

Family

ID=9461466

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95914403T Expired - Lifetime ES2134459T3 (es) 1994-03-28 1995-03-23 Indeno(1,2-e)pirazina-4-onas, su preparacion y los medicamentos que les contienen.

Country Status (13)

Country Link
US (1) US5789406A (es)
EP (1) EP0752991B1 (es)
JP (1) JPH09510726A (es)
AT (1) ATE180483T1 (es)
AU (1) AU2141295A (es)
DE (1) DE69509888T2 (es)
DK (1) DK0752991T3 (es)
ES (1) ES2134459T3 (es)
FR (1) FR2717812B1 (es)
GR (1) GR3030273T3 (es)
IL (1) IL113147A0 (es)
WO (1) WO1995026349A1 (es)
ZA (1) ZA952531B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2743366B1 (fr) * 1996-01-10 1998-02-06 Rhone Poulenc Rorer Sa Derives de 5h,10h-imidazo(1,2-a)indeno(1,2-e)pyrazine-4-one, leur preparation, leurs intermediaires et les medicaments les contenant
KR20030082982A (ko) * 2001-03-14 2003-10-23 그뤼넨탈 게엠베하 치환된 피라졸로피리미딘 및 티아졸로피리미딘
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
CN102791704B (zh) 2010-03-10 2015-11-25 前体生物药物股份公司 谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4400382A (en) * 1980-05-09 1983-08-23 Usv Pharmaceutical Corporation Thiazoloquinoxalin-1,4-diones for treating allergy
US4668678A (en) * 1980-05-09 1987-05-26 Usv Pharmaceutical Corporation Triazoloquinoxalin-1,4-diones
US4507300A (en) * 1980-05-09 1985-03-26 Usv Pharmaceutical Corporation Pyridotriazolopyrazine-diones for treating allergy
US4354027A (en) * 1980-05-19 1982-10-12 Usv Pharmaceutical Corporation Triazoloquinoxalin-4-ones
US5191197A (en) * 1988-05-11 1993-03-02 Symbol Technologies, Inc. Arm mounted scanner actuatable by hand movement
US5153196A (en) * 1991-06-05 1992-10-06 Eli Lilly And Company Excitatory amino acid receptor antagonists and methods for the use thereof
US5196421A (en) * 1991-06-05 1993-03-23 Eli Lilly And Company Excitatory amino acid receptor antagonists in methods for the use thereof
DK162491D0 (da) * 1991-09-20 1991-09-20 Novo Nordisk As Heterocycliske forbindelser, deres fremstilling og farmaceutiske praeparater indeholdende forbindelserne
KR100304017B1 (ko) * 1992-06-22 2001-11-22 추후제출 글리신수용체길항물질및이의용도
FR2696466B1 (fr) * 1992-10-02 1994-11-25 Rhone Poulenc Rorer Sa Dérivés de 5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, leur préparation et les médicaments les contenant.
DK12293D0 (da) * 1993-02-02 1993-02-02 Novo Nordisk As Heterocykliske forbindelser og deres fremstilling og anvendelse
FR2707643B1 (fr) * 1993-07-16 1995-08-11 Rhone Poulenc Rorer Sa Dérivés d'imidazo[1,2-a]pyrazine-4-one, leur préparation et les médicaments les contenant.
FR2707645B1 (fr) * 1993-07-16 1995-08-11 Rhone Poulenc Rorer Sa Dérivés d'imidazo[1,2-a]pirazine-4-one, leur préparation et les médicaments les contenant.

Also Published As

Publication number Publication date
ZA952531B (en) 1996-01-11
DE69509888T2 (de) 1999-09-30
EP0752991B1 (fr) 1999-05-26
FR2717812A1 (fr) 1995-09-29
AU2141295A (en) 1995-10-17
DK0752991T3 (da) 1999-11-08
FR2717812B1 (fr) 1996-05-10
US5789406A (en) 1998-08-04
IL113147A0 (en) 1995-06-29
WO1995026349A1 (fr) 1995-10-05
ATE180483T1 (de) 1999-06-15
JPH09510726A (ja) 1997-10-28
EP0752991A1 (fr) 1997-01-15
GR3030273T3 (en) 1999-08-31
DE69509888D1 (de) 1999-07-01

Similar Documents

Publication Publication Date Title
ES2134460T3 (es) Derivados de 5h-indeno(1,2-b)-pirazina-2,3-diona, su preparacion y los medicamentos que les contienen.
ES2134459T3 (es) Indeno(1,2-e)pirazina-4-onas, su preparacion y los medicamentos que les contienen.
DK0711280T3 (da) Perhydroisoindolderivater, fremstilling af disse forbindelser og farmaceutiske præparater indeholdende disse forbindelser
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
ES2158099T3 (es) Derivados de imidazo(1,2-a)indeno(1,2-e)pirazina-4-ona y composiciones farmaceuticas que los contienen.
DK0756602T3 (da) CCK- eller gastrin-modulerende 5-heterocyclo-1,5-benzodiazepiner
FI971528A (fi) Pyrrolyylitetrahydrobentsokinoksaliinidionit, niiden valmistus ja käyttö glutamaattireseptoriantagonisteina

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 752991

Country of ref document: ES